You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Express Scripts
Mallinckrodt
Merck
Boehringer Ingelheim

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PROVENGE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Provenge

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01385293 BKM120 in Metastatic Castration-resistant Prostate Cancer Active, not recruiting Novartis Pharmaceuticals Phase 2 2011-08-01 The purpose of this study is to evaluate the effects of the study drug, BKM120. The study drug, BKM120, is an inhibitor of a protein called phosphatidyl inositol-3-kinase (PI3K). This protein is found in normal cells and in cancer cells, but often in many cancer cells this protein is overactive. Inhibiting the protein may slow the growth of prostate cancer but this has not been tested yet in men with prostate cancer.
NCT01385293 BKM120 in Metastatic Castration-resistant Prostate Cancer Active, not recruiting Andrew J. Armstrong, MD Phase 2 2011-08-01 The purpose of this study is to evaluate the effects of the study drug, BKM120. The study drug, BKM120, is an inhibitor of a protein called phosphatidyl inositol-3-kinase (PI3K). This protein is found in normal cells and in cancer cells, but often in many cancer cells this protein is overactive. Inhibiting the protein may slow the growth of prostate cancer but this has not been tested yet in men with prostate cancer.
NCT01420965 Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer Suspended Augusta University Phase 2 2012-09-01 Background: - Sipuleucel-T is a new treatment for advanced stage prostate cancer. It takes cells from a person with prostate cancer and treats them in the laboratory. Then it returns the cells to the person to help the immune system fight the cancer. Sipuleucel-T may be combined with the drug CT-011 to boost its ability to kill cancer cells. The chemotherapy drug cyclophosphamide will also be given, either before or after the cells are collected at the start of the treatment. Objectives: - To test the effectiveness of Sipuleucel-T, CT-011, and cyclophosphamide for prostate cancer. Eligibility: - Men at least 18 years of age who have advanced prostate cancer. Design: - Participants will be screened with a medical history, physical exam, blood and urine tests, and imaging studies. - This study has two parts, with different participants in each part. All participants will be monitored with frequent blood tests and imaging studies. - Part I: - Participants will provide cells for the Sipuleucel-T treatment three times. The first time will be 3 days before the chemotherapy. The second time will be 10 days after chemotherapy. The third time will be 24 days after chemotherapy. - Participants will have one dose of cyclophosphamide the day before the first dose of Sipuleucel-T. - Participants will have Sipuleucel-T about 3 days after each cell donation. - Part II: - Participants will be in three groups: Sipuleucel-T given alone, given with CT-011, or given with both cyclophosphamide and CT-011. - Participants will provide cells for the Sipuleucel-T treatment three times, as in Part I. - Participants will have Sipuleucel-T about 3 days after each cell donation, and will receive treatment with the other drugs as directed by the study doctors.
NCT01804465 A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer Recruiting Bristol-Myers Squibb Phase 2 2014-01-01 The purpose of this study is to find out what effects taking ipilimumab, as an immediate or delayed treatment, following completion of sipuleucel-T (SipT) treatment, has on patients and their prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Provenge

Condition Name

Condition Name for Provenge
Intervention Trials
Prostate Cancer 8
Metastatic (Spread to Other Areas of the Body) 1
Recurrent Prostate Carcinoma 1
mCRPC 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Provenge
Intervention Trials
Prostatic Neoplasms 13
Carcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Provenge

Trials by Country

Trials by Country for Provenge
Location Trials
United States 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Provenge
Location Trials
Texas 4
North Carolina 3
California 2
Arizona 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Provenge

Clinical Trial Phase

Clinical Trial Phase for Provenge
Clinical Trial Phase Trials
Phase 2 9
Phase 1/Phase 2 1
Phase 1 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Provenge
Clinical Trial Phase Trials
Recruiting 5
Not yet recruiting 3
Active, not recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Provenge

Sponsor Name

Sponsor Name for Provenge
Sponsor Trials
Dendreon 2
Duke University 2
The University of Texas Health Science Center, Houston 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Provenge
Sponsor Trials
Other 14
Industry 5
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Medtronic
Colorcon
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.